

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-333**

**APPROVAL LETTER**



NDA 21-333

Ferring Pharmaceuticals Inc.  
Attention: Ronald V. Nardi, Ph.D.  
Executive Vice President and Chief Scientific Officer  
120 White Plains Road, Suite 400  
Tarrytown, New York 10591

Dear Dr. Nardi:

Please refer to your new drug application (NDA) dated October 27, 2000, received November 3, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Desmopressin Acetate Nasal Spray.

We acknowledge receipt of your submissions dated July 14 and 18, 2002. Your submission of July 14, 2002, constituted a complete response to our August 29, 2001, action letter.

This new drug application provides for the use of a refrigerated formulation of Desmopressin Acetate Nasal Spray for primary nocturnal enuresis and for the management of central cranial diabetes insipidus.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed upon labeling text.

The final printed labeling (FPL) must be identical to the submitted labeling (package insert submitted July 14, 2002 [enclosed], patient package insert (submitted July 14, 2002 [enclosed], immediate container and carton labels submitted July 18, 2002). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved NDA 21-333." Approval of this submission by FDA is not required before the labeling is used.

Please note, if you choose to use a proprietary name for this product, the name and its use in the label must conform to the specifications under 21 CFR 201.10 and 201.15. We recommend that you submit any proprietary name to the Agency for our review prior to its implementation.

NDA 21-333

Page 2

Be advised that, as of April 1, 1999, all applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred (63 *FR* 66632). We are waiving the pediatric study requirement for primary nocturnal enuresis in children less than 6 years. For central diabetes insipidus treatment in children 0 to 3 months, we are deferring the pediatric studies requirement. We request that you submit published literature to evaluate whether data are adequate to support this population.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

Validation of the regulatory methods has not been completed. At the present time, it is the policy of the Center not to withhold approval because the methods are being validated. Nevertheless, we expect your continued cooperation to resolve any problems that may be identified.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Steve McCort, Regulatory Project Manager, at (301) 827-6415.

Sincerely,

David G. Orloff, M.D.  
Director  
Division of Metabolic and  
Endocrine Drug Products, HFD-510  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**21-333**

**APPROVABLE LETTER**



NDA 21-333

Ferring Laboratories Inc.  
Attention: Ronald V. Nardi, Ph.D.  
Vice President, Scientific Affairs  
120 White Plains Road, Suite 400  
Tarrytown, NY 10591

Dear Dr. Nardi:

Please refer to your new drug application (NDA) dated October 27, 2000, received November 3, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Desmopressin Acetate Nasal Spray, 100 mcg/ml.

We acknowledge receipt of your submissions dated January 10, April 12, July 3, and August 13, 2001.

The new drug application proposes the use of a refrigerated formulation of Desmopressin Acetate Nasal Spray in the management of temporary nocturnal enuresis, in the management of central or cranial diabetes, and for the management of temporary polyuria and polydypsia following head trauma or surgery in the pituitary region.

We have completed the review of this application, as amended, and it is approvable. Before this application may be approved, however, it will be necessary for you to address the following:

During recent inspections of the manufacturing facilities for your NDA, a number of deficiencies were noted and were subsequently conveyed to you or your suppliers by the investigator. Satisfactory inspections will be required before this application may be approved.

When you respond to the above deficiency, please provide draft labeling with the following change:

In the **CLINICAL PHARMACOLOGY** section, delete the phrase "nasal spray" from the second sentence of the **Pharmacokinetics** subsection.

If additional information relating to the safety or effectiveness of this drug becomes available, revision of the labeling may be required.

NDA 21-333

Page 2

Within 10 days after the date of this letter, you are required to amend the application, notify us of your intent to file an amendment, or follow one of your other options under 21 CFR 314.110. In the absence of any such action FDA may proceed to withdraw the application. Any amendment should respond to all the deficiencies listed. We will not process a partial reply as a major amendment nor will the review clock be reactivated until all deficiencies have been addressed.

The drug product may not be legally marketed until you have been notified in writing that the application is approved.

If you have any questions, call Steve McCort, Regulatory Project Manager, at (301) 827-6415.

Sincerely,

*{See appended electronic signature page}*

David G. Orloff, M.D.  
Director  
Division of Metabolic and Endocrine Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**

/s/

-----  
David Orloff  
8/29/01 06:56:45 PM